Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | The impact of COVID-19 on CAR-T therapy

Bruce Levine • 28 May 2020
General

Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, updates us on the impact on COVID-19 on the delivery of CAR-T therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Bruce Levine

CAR-T therapy: where is it going?
1:15
CAR-T therapy: where is it going?
Bruce Levine • 28 May 2020
ISCT 2020: Moving ahead at full speed session - what can delegates look forward to?
1:20
ISCT 2020: Moving ahead at full speed session - what can delegates look forward to?
Bruce Levine • 28 May 2020
ISCT 2020: looking forward to advances and emerging technologies in immune-mediated cancer therapy
1:00
ISCT 2020: looking forward to advances and emerging technologies in immune-mediated cancer therapy
Bruce Levine • 28 May 2020
Translation from academia to industry: manufacturing of CAR T-cells
1:29
Translation from academia to industry: manufacturing of CAR T-cells
Bruce Levine • 30 Jan 2020

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals